China Summit paves the way for Australian companies
11 March, 2014Recognising the leading role China will take globally in the future of life sciences, AusBiotech recently presented the second Australia China Life Science Summit in Sydney and now continues to pave the way for Australian companies interested in opportunities in and with China.
Fibrotech completes phase Ia trial, moves to 1b
11 March, 2014 by Dylan Bushell-EmblingFibrotech said a phase Ia trial has demonstrated the safety of antifibrotic candidate FT011 in healthy volunteers, and revealed the company has started dosing for a phase IIb study.
Mesoblast appoints new director
10 March, 2014 by Dylan Bushell-EmblingMesoblast's new non-executive director, former Roche Pharmaceuticals CEO William Burns, is excited about the prospects for regenerative medicine.
Call for EOI to showcase SME medtech success
06 March, 2014Medical and Scientific Technologies Supplier Advocate Dr Greg Roger is seeking case studies to promote and raise awareness of the capabilities of Australian SMEs in the medical and scientific technology field, facilitate collaboration opportunities and share lessons learned.
PolyNovo gets US tick for NovoPore dressing
06 March, 2014 by Dylan Bushell-EmblingCalzada's (ASX:CZD) PolyNovo subsidiary has won 510(k) approval in the US for TNP foam dressing NovoPore, which has become the first approved product based on its NovoSorb technology.
Neuren well funded for clinical trials
05 March, 2014 by Dylan Bushell-EmblingNeuren's (ASX:NEU) cash balance of $25m should be enough to fund key clinical trials of neurological drug candidate NNZ-2566 through to the expected receipt of licensing revenue in 2015, Bell Potter says.
AusBiotech articulates support for tax reform
04 March, 2014Building on the strategic plan that was presented at the AusBiotech national conference in November by AusBiotech Chair Dr Deborah Rathjen, the organisation is continuing its call for further tax reform in Australia.
New appointments at ANSTO
04 March, 2014ANSTO's CEO, Dr Adrian (Adi) Paterson, has been reappointed and businessman James McDowell has joined the ANSTO board.
Mesoblast well funded for next 2-3 years
04 March, 2014 by Dylan Bushell-EmblingBell Potter Securities has maintained its 'buy' rating for Mesoblast shares - with a slightly reduced price target - on the strength of the company's 1H14 results.
Phosphagenics names new board
03 March, 2014 by Dylan Bushell-EmblingLaurence Gozlan, Nathan Drona and Dr Geert Cauwenbergh have joined Phosphagenics (ASX:POH) as non-executive directors.
Fibrotech secures patents in NA for fibrosis drugs
03 March, 2014 by Dylan Bushell-EmblingFibrotech Therapeutics has been awarded patents in the US and Canada covering its portfolio of antifibrotic drug candidates.
Calzada appoints new director, posts 1H14 results
28 February, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) has appointed David Williams as a non-executive director and revealed it improved its cash position during 1H14.
Government announces funding for cancer and hearing CRCs in latest round
27 February, 2014In the latest announcement dedicating almost $186 million in funding, the federal government will create three new cooperative research centres (CRCs) and extend four existing CRCs, including the Hearing CRC and the Cancer Therapeutics CRC, to drive research that will deliver practical benefits.
No progress for Pharma Patents Review
26 February, 2014No plan to release the Pharmaceutical Patents Review Report, says Minister for Industry, Ian Macfarlane.
Immuron closes $9.6m rights issue
26 February, 2014 by Dylan Bushell-EmblingImmuron (ASX:IMC) has completed a $9.66m capital raising, giving it funds to commence a phase IIb trial of its liver disease drug candidate in nonalcoholic steatohepatitis (NASH).
